PMID- 28721150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1734-1922 (Print)
IS  - 1896-9151 (Electronic)
IS  - 1734-1922 (Linking)
VI  - 13
IP  - 4
DP  - 2017 Jun
TI  - Phenotype distribution of the paraoxonase gene in patients with cardiac disease.
PG  - 820-826
LID - 10.5114/aoms.2016.59674 [doi]
AB  - INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic 
      properties including arylesterase and lactonase activities besides its ability to 
      hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was 
      to determine the phenotype distribution of PON1 in patients with cardiac disease 
      who were classified in coronary artery bypass grafting (CABG), heart valve 
      disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) 
      groups and healthy subjects as a control group. MATERIAL AND METHODS: A total of 
      300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients 
      and 100 healthy controls) were admitted to this study. Individual variations in 
      PON1 were determined using the dual substrate (paraoxon and phenylacetate) 
      method. RESULTS: The following phenotype distributions were found in the cardiac 
      disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% 
      (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high 
      activity) phenotypic distribution was more common in the cardiac disease group 
      than in controls (p = 0.04). In particular, the frequency of the RR phenotype was 
      two- to three-fold higher in the STEMI and HF patients compared to the controls 
      as well as CABG and HVD groups. CONCLUSIONS: We found a higher percentage of RR 
      phenotype in STEMI and HF patients compared to a large control group as well as 
      compared to two other groups of cardiac disease patients.
FAU - Ellidag, Hamit Yasar
AU  - Ellidag HY
AD  - Department of Biochemistry, Antalya Education and Research Hospital, Antalya, 
      Turkey.
FAU - Aydin, Ozgur
AU  - Aydin O
AD  - Biochemistry Laboratory, Maternity and Children's Hospital, Batman, Turkey.
FAU - Eren, Esin
AU  - Eren E
AD  - Department of Biochemistry, Antalya Education and Research Hospital, Antalya, 
      Turkey.
FAU - Yilmaz, Necat
AU  - Yilmaz N
AD  - Department of Biochemistry, Antalya Education and Research Hospital, Antalya, 
      Turkey.
FAU - Gencpinar, Tugra
AU  - Gencpinar T
AD  - Cardiovascular Surgery Clinic, Education and Research Hospital, Antalya, Turkey.
FAU - Kucukseymen, Selcuk
AU  - Kucukseymen S
AD  - Clinic of Cardiology, Antalya Education and Research Hospital of Ministry of 
      Health, Antalya, Turkey.
FAU - Yilmaz, Akar
AU  - Yilmaz A
AD  - Clinic of Cardiology, Antalya Education and Research Hospital of Ministry of 
      Health, Antalya, Turkey.
FAU - Arslan Ince, Fatma Demet
AU  - Arslan Ince FD
AD  - Department of Biochemistry, Tepecik Education and Research Hospital of Ministry 
      of Health, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20160525
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC5510503
OTO - NOTNLM
OT  - arylesterase
OT  - heart diseases
OT  - high-density lipoprotein
OT  - lipids
OT  - oxidative stress
EDAT- 2017/07/20 06:00
MHDA- 2017/07/20 06:01
PMCR- 2017/06/01
CRDT- 2017/07/20 06:00
PHST- 2015/04/12 00:00 [received]
PHST- 2015/06/05 00:00 [accepted]
PHST- 2017/07/20 06:00 [entrez]
PHST- 2017/07/20 06:00 [pubmed]
PHST- 2017/07/20 06:01 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 27481 [pii]
AID - 10.5114/aoms.2016.59674 [doi]
PST - ppublish
SO  - Arch Med Sci. 2017 Jun;13(4):820-826. doi: 10.5114/aoms.2016.59674. Epub 2016 May 
      25.